XML 81 R59.htm IDEA: XBRL DOCUMENT
v3.26.1

License Agreement (Details Narrative) - USD ($) $ in Millions |  | 1 Months Ended
--- | --- | ---
Apr. 08, 2021 | Jun. 30, 2025
Pfizer License Agreement [Member] |  |
Payment for upfront fees | $ 5.0 |
Pfizer License Agreement [Member] | Common Stock [Member] |  |
Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement | 349,406 |
License Agreement [Member] |  |
Payment on milestone event one | $ 5.0 |
Research and development expense |  | $ 5.0
License Agreement [Member] | Maximum [Member] |  |
Aggregate value of milestone events | $ 335.0 |

X
- Definition Aggregate value of milestone events + References No definition available. + Details
Name: | CELC_AggregateValueOfMilestoneEvents
Namespace Prefix: | CELC_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payment on milestone event one. + References No definition available. + Details
Name: | CELC_PaymentOnMilestoneEventOne
Namespace Prefix: | CELC_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development expense. + References No definition available. + Details
Name: | CELC_ResearchAndDevelopmentExpenseMilestone
Namespace Prefix: | CELC_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=CELC_PfizerLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=CELC_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |